U.S. Women’s Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Contraceptives, Menopause, PCOS), By Age, By Drug Class, And Segment Forecasts, 2025 - 2030
U.S. Women’s Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Contraceptives, Menopause, PCOS), By Age, By Drug Class, And Segment Forecasts, 2025 - 2030
Dry Eye Syndrome Treatment Market Growth & Trends
The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.
The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.
Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.
Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.
Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.
By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period
Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024
By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.
Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate
Please note The report will be delivered in 2-3 business days upon order notification.
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Age
1.2.3. Drug
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database.
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in U.S.
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. Age outlook
2.2.3. Drug outlook.
2.3. Competitive Insights
Chapter 3. U.S. Women’s Health Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of target diseases
3.2.1.2. Increasing initiatives by government and various organizations
3.2.1.3. Rising publicly funded family planning services
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of major drugs
3.2.2.2. Lawsuits related to products.
3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
3.3. U.S. Women’s Health Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
Chapter 4. U.S. Women’s Health Market: Application Estimates & Trend Analysis
4.1. Application Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Women’s Health Market by Application Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Hormonal infertility
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Contraceptives
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Postmenopausal osteoporosis
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Endometriosis & uterine fibroids
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Menopause
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Polycystic ovary syndrome (PCOS)
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Women’s Health Market: Drug Class Estimates & Trend Analysis
5.1. Drug Class Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Women’s Health Market by Drug Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hormonal Therapies
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Bone Health Agents
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Fertility Agents
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. GnRH Modulators
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Pain and Symptom Management
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Metabolic Agents
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Others
5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Women’s Health Market: Age Estimates & Trend Analysis
6.1. Age Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Women’s Health Market by Age Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. 50 years and above
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2. Postmenopausal osteoporosis
6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3. Endometriosis & uterine fibroids
6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.4. Menopause
6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.5. Others
6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Others
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners